Allocation of note proceeds to site acquisitions
Company: Core Scientific
The claim, verbatim
Of the ~$2.9B in net proceeds, $700–900M is illustratively allocated to new site acquisitions. The remaining ~$2.0–2.2B of development equity, leveraged at 80% LTC, would support ~1 GW+ of new capacity.
Source (primary)
First Quarter Fiscal Year 2026 Earnings Presentation (IR page (investors.corescientific.com), ir_presentation)
View cached copy (2026-10-16)Live source ↗Archive.org ↗
Quote: “New Site Acquisitions: ($700–900M) Remaining Development Equity: ~$2.0–2.2B Leveraged at 80% project finance LTC Supports ~1 GW+ of new capacity development”
How we checked this
Checked on October 17, 2026. The cited source supports every part of this claim.
The illustrative uses of proceeds slide shows each of these figures.
Confirmed in the source:
- Net proceeds are ~$2.9B
- $700–900M is illustratively allocated to new site acquisitions
- Remaining development equity is ~$2.0–2.2B
- The development equity is leveraged at 80% project finance LTC
- This supports ~1 GW+ of new capacity development
What we did: Read our cached copy of IR page (investors.corescientific.com) (https://d1io3yog0oux5.cloudfront.net/_b76ddaa46c59e7a64138659274ff5f32/corescientific/db/1066/11271/pdf/Q1+FY26+earnings+deck.pdf) in full (14,811 characters, retrieved October 16, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms First Quarter Fiscal Year 2026 Earnings Presentation
Quote: “New Site Acquisitions: ($700–900M) Remaining Development Equity: ~$2.0–2.2B Leveraged at 80% project finance LTC Supports ~1 GW+ of new capacity development”